Clinical Trials Browser

Phase 3 × Completed × Azacitidine × Clear all

Leukemia, Myeloid, Acute

NCT04102020 2026-04-08

VIALE-M

Phase 3 Completed

112 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

371 enrolled 36 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03268954 2025-10-29

PANTHER

Phase 3 Completed

454 enrolled 41 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Phase 3 Completed

183 enrolled 30 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 1 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02577406 2025-05-18

IDHENTIFY

Phase 3 Completed

319 enrolled 29 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid

NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Phase 3 Completed

154 enrolled 10 charts

MDS

NCT04842604 2023-12-18

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Phase 3 Completed

14 enrolled 11 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05188326 2023-06-08

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Phase 3 Completed

54 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03416179 2023-04-21

BRIGHT AML1019

Phase 3 Completed

730 enrolled 35 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Phase 3 Completed

60 enrolled 12 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT00887068 2020-01-14

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Phase 3 Completed

187 enrolled 9 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01074047 2017-08-29

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Phase 3 Completed

488 enrolled 46 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Viale-a

VIALE-M

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

PANTHER

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

QUAZAR AML-001

IDHENTIFY

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

BRIGHT AML1019

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)